Presentation of Immune Response Data to Intratumoural Injections of CAVATAK in Late Stage Melanoma Patients

PYMBLE, Australia, Sept. 11, 2008-A poster covering immune response data obtained from late stage melanoma patients administered intratumoural injections of CAVATAKTM will be presented at the HMRI Conference on Translational Cancer Research to be held September 10-12, 2008 in Newcastle. The poster to be presented by Dr. Darren Shafren addresses serum immune responses produced by late stage melanoma patients following two intratumoural injections of CAVATAKTM. The preliminary data have been generated from the current Phase I dose escalation trial of CAVATAKTM in late stage melanoma patients (Clinical Trials.gov Identifier: NCT00438009).


The poster presentation will be available on the Viralytics website (www.viralytics.com) today, in the Scientific Publications Section.
 

Bryan Dulhunty
Chairman

About Viralytics Ltd.
Viralytics is listed on the Australian Stock Exchange (ASX code: VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics’ principal asset is the intellectual property relating to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics’ proprietary formulation of the Coxsackievirus Type A21 (CVA21). CVA21 is a human virus that occurs naturally in the community. CVA21 attaches to the outside of a cell, using a specific ‘receptor’ on the cell’s surface (like a key fitting a lock). CVA21 uses two receptors to infect cells, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF). Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including:
melanoma, prostate cancer, breast cancer, multiple myeloma and others.

 

 

Posted: September 2008

View comments

Hide
(web1)